Multicenter clinical trial using an accelerated streptokinase regimen in patients with acute myocardial infarction

Chinese Medical Journal

Volumn 113, Issue 8, 2000, Pages 733-736

  Xu, Chengbin ^a   Zhang, Tong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Accelerated streptokinase; Myocardial infarction; Thrombolytic therapy

Indexed keywords

STREPTOKINASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 0342656198     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-585.
2. Gruppo Italiano per lo Studio della Streptochinasi nell Infarto miocardioco (GISSI) . Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
3. ISIS-2 (Second international study of infarct survival) Collaborative Group. Randomized trial of intravenous streptokinase, or oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-360.
4. GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
5. ISIS-3 (Third international study of infarct survival) Collaborative Group. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
7. Wall TC, Califf RM, George BS, et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis. J Am Coll Cardiol 1992;19:482-489.
8. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-855.
9. White HD, Rivers JT, Maslowski AH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989;320:817-821.
10. The collaborative study group for national multicenter clinical trial of streptokinase thrombolytic therapy. A report on multicenter clinical trial of intravenous thrombolytic therapy using streptokinase in patients with acute myocardial infarction. Chin J Cardiol 1994;22:403-405.